Dr. Eliott is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Harvard Medical School
243 Charles St
Boston, MA 02114Phone+1 617-573-3701
Summary
- Dr. Dean Eliott is a retina specialist in Boston, MA and is affiliated with multiple hospitals in the area, including Massachusetts General Hospital, Brigham and Women's Hospital, and Massachusetts Eye and Ear. He received his medical degree from Vanderbilt University School of Medicine and has been in practice 30 years. He is experienced in diabetic retinopathy, macular degeneration, retina surgery, and vitreoretinal disease. He has more than 300 publications.
Education & Training
- Duke University HospitalChief Residency, Ophthalmology, 1993 - 1994
- Duke University HospitalFellowship, Surgical Retina and Vitreous, 1992 - 1993
- Johns Hopkins UniversityResidency, Ophthalmology, 1989 - 1992
- New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1988 - 1989
- Vanderbilt University School of MedicineClass of 1988
Certifications & Licensure
- CA State Medical License 2006 - Present
- MA State Medical License 2011 - 2025
- MI State Medical License 1994 - 2007
- NC State Medical License 1992 - 1998
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Avastin for PDR (Proliferative Diabetic Retinopathy) Start of enrollment: 2009 Jun 01
- Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration Start of enrollment: 2011 Jun 09
- Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD Start of enrollment: 2013 Feb 25
Publications & Presentations
PubMed
- Targeting the Tie-2 Receptor With Faricimab in Central Serous Chorioretinopathy: A Case Series Motivated by a Genetic Finding.Joel T Rämö, Leo A Kim, Tomasz Stryjewski, Priya P Shah, Romy Bejjani
American Journal of Ophthalmology. 2025-01-01 - Visual Outcomes and Risk of Endophthalmitis in Open Globe Injuries without Intraocular Foreign Bodies with Delayed Repair.Marisa G Tieger, Nakul Singh, Racquel Bitar, Kevin Makhoul, Helia Ashourizadeh
Ophthalmology. 2024-12-01 - An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental models.Michael O'Hare, William P Miller, Said Arevalo-Alquichire, Dhanesh Amarnani, Evhy Apryani
Science Translational Medicine. 2024-11-27
Press Mentions
- He Kept Seeing Sparkly Dots on the Edge of His Vision. What Was It?June 16th, 2021
- Scleral Buckle Infection with Pseudallescheria BoydiiSeptember 23rd, 2020
- Predictive Value of the OCT Double-Layer Sign for Identifying Subclinical Neovascularization in Age-Related Macular DegenerationOctober 30th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: